StreetInsider.com News Articles

StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 11:40:11 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Bioxytran reports positive results from COVID-19 antiviral trial http://www.streetinsider.com/FDA/Bioxytran+reports+positive+results+from+COVID-19+antiviral+trial/26089583.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 1b/2a clinical study of its oral antiviral drug ProLectin-M in hospitalized patients with mild to moderate COVID-19. The randomized, double-blind, placebo-controlled study enrolled 39 participants in India.</p> <p>The study showed that patients receiving the highest dose of ProLectin-M at 16,800 mg per day achieved statistically significant earlier viral clearance compared to placebo. By Day 5, 90% of participants in the highest-dose group achieved non-detectable viral shedding, compared to 20% in the placebo group. The difference was statistically significant with a p-value of 0.001.</p> <p>Clinical improvement also occurred faster in the highest-dose group, with http://www.streetinsider.com/FDA/Bioxytran+reports+positive+results+from+COVID-19+antiviral+trial/26089583.html Mon, 02 Mar 2026 11:40:11 +0000 BIXT Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html <p><strong id="dateline">BOSTON, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.</p><p>The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html Mon, 02 Mar 2026 11:40:00 +0000 BIXT Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 http://www.streetinsider.com/ACCESS+Newswire/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html <p><strong id="dateline">BOSTON, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.</p><p>The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all http://www.streetinsider.com/ACCESS+Newswire/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html Mon, 02 Mar 2026 11:40:00 +0000 BIXT Form 8-K BIOXYTRAN, INC For: Mar 02 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html si-local-file:///var/storage/secattach/20260302/26088329.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html Mon, 02 Mar 2026 09:22:00 +0000 BIXT O.07604345 Form 8-K BIOXYTRAN, INC For: Mar 02 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html si-local-file:///var/storage/secattach/20260302/26088329.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html Mon, 02 Mar 2026 09:22:00 +0000 BIXT O.07604345 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran's novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 +0000 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Announces+Commercial+Distribution+Agreement+with+Khoury+Medical+LTD+for+A-SUQAR+Dietary+Supplement/26008787.html <p>BOSTON, Massachusetts, Feb 17, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCMKTS: BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements.</p><p>Under the agreement, Khoury Medical will commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets in accordance with the Distribution Agreement. The product is marketed as a dietary http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Announces+Commercial+Distribution+Agreement+with+Khoury+Medical+LTD+for+A-SUQAR+Dietary+Supplement/26008787.html Tue, 17 Feb 2026 07:00:00 +0000 BIXT O.07604345 Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Announces+Commercial+Distribution+Agreement+with+Khoury+Medical+LTD+for+A-SUQAR+Dietary+Supplement/26008787.html <p>BOSTON, Massachusetts, Feb 17, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCMKTS: BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements.</p><p>Under the agreement, Khoury Medical will commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets in accordance with the Distribution Agreement. The product is marketed as a dietary http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Announces+Commercial+Distribution+Agreement+with+Khoury+Medical+LTD+for+A-SUQAR+Dietary+Supplement/26008787.html Tue, 17 Feb 2026 07:00:00 +0000 BIXT O.07604345 Form 8-K BIOXYTRAN, INC For: Feb 10 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+10/26005276.html si-local-file:///var/storage/secattach/20260217/26005276.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+10/26005276.html Tue, 17 Feb 2026 06:21:00 +0000 BIXT O.07604345 Form 8-K BIOXYTRAN, INC For: Feb 10 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+10/26005276.html si-local-file:///var/storage/secattach/20260217/26005276.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+10/26005276.html Tue, 17 Feb 2026 06:21:00 +0000 BIXT O.07604345 Bioxytran reports viral clearance in phase 2 trial of ProLectin-M http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 2 trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo group participants.</p> <p>The randomized, double-blind, placebo-controlled trial enrolled 38 subjects with laboratory-confirmed acute viral infection. Participants received one of three ProLectin-M dose levels or placebo over seven days. All subjects completed the study.</p> <p>Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs. The company reported 100% of treated subjects achieved complete viral elimination by day 7, with statistical significance of p=.001 versus placebo. No viral rebounds occurred during a 14-day post-treatment observation period.</p> <p>According to http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html Wed, 11 Feb 2026 07:47:59 +0000 A.50215973 BIXT O.07146130 O.07604345 Bioxytran reports viral clearance in phase 2 trial of ProLectin-M http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 2 trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo group participants.</p> <p>The randomized, double-blind, placebo-controlled trial enrolled 38 subjects with laboratory-confirmed acute viral infection. Participants received one of three ProLectin-M dose levels or placebo over seven days. All subjects completed the study.</p> <p>Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs. The company reported 100% of treated subjects achieved complete viral elimination by day 7, with statistical significance of p=.001 versus placebo. No viral rebounds occurred during a 14-day post-treatment observation period.</p> <p>According to http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html Wed, 11 Feb 2026 07:47:59 +0000 A.50215973 BIXT O.07146130 O.07604345 Bioxytran reports viral clearance in phase 2 trial of ProLectin-M http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 2 trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo group participants.</p> <p>The randomized, double-blind, placebo-controlled trial enrolled 38 subjects with laboratory-confirmed acute viral infection. Participants received one of three ProLectin-M dose levels or placebo over seven days. All subjects completed the study.</p> <p>Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs. The company reported 100% of treated subjects achieved complete viral elimination by day 7, with statistical significance of p=.001 versus placebo. No viral rebounds occurred during a 14-day post-treatment observation period.</p> <p>According to http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html Wed, 11 Feb 2026 07:47:59 +0000 A.50215973 BIXT O.07146130 O.07604345 Bioxytran reports viral clearance in phase 2 trial of ProLectin-M http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 2 trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo group participants.</p> <p>The randomized, double-blind, placebo-controlled trial enrolled 38 subjects with laboratory-confirmed acute viral infection. Participants received one of three ProLectin-M dose levels or placebo over seven days. All subjects completed the study.</p> <p>Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs. The company reported 100% of treated subjects achieved complete viral elimination by day 7, with statistical significance of p=.001 versus placebo. No viral rebounds occurred during a 14-day post-treatment observation period.</p> <p>According to http://www.streetinsider.com/FDA/Bioxytran+reports+viral+clearance+in+phase+2+trial+of+ProLectin-M/25979554.html Wed, 11 Feb 2026 07:47:59 +0000 A.50215973 BIXT O.07146130 O.07604345 Form 8-K BIOXYTRAN, INC For: Feb 11 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+11/25978747.html si-local-file:///var/storage/secattach/20260211/25978747.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+11/25978747.html Wed, 11 Feb 2026 06:05:00 +0000 BIXT O.07604345 Form 8-K BIOXYTRAN, INC For: Feb 11 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+11/25978747.html si-local-file:///var/storage/secattach/20260211/25978747.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Feb+11/25978747.html Wed, 11 Feb 2026 06:05:00 +0000 BIXT O.07604345 Bioxytran reports complete viral clearance in phase 2 antiviral trial http://www.streetinsider.com/FDA/Bioxytran+reports+complete+viral+clearance+in+phase+2+antiviral+trial/25978409.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a phase 2 clinical trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo. The randomized, double-blind, placebo-controlled study evaluated the company's ProLectin-M treatment in 38 subjects with laboratory-confirmed acute viral infection.</p> <p>The trial achieved statistical significance with a p-value of 0.001 for complete viral clearance at day 7. All 38 subjects completed the seven-day treatment period, receiving either one of three ProLectin-M dose levels or matching placebo. Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs, with clearance defined as non-detection of viral RNA below http://www.streetinsider.com/FDA/Bioxytran+reports+complete+viral+clearance+in+phase+2+antiviral+trial/25978409.html Wed, 11 Feb 2026 06:00:27 +0000 A.50215973 BIXT O.07146130 O.07604345 Bioxytran reports complete viral clearance in phase 2 antiviral trial http://www.streetinsider.com/FDA/Bioxytran+reports+complete+viral+clearance+in+phase+2+antiviral+trial/25978409.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a phase 2 clinical trial showing complete elimination of viral load in all treated patients by day 7 compared to placebo. The randomized, double-blind, placebo-controlled study evaluated the company's ProLectin-M treatment in 38 subjects with laboratory-confirmed acute viral infection.</p> <p>The trial achieved statistical significance with a p-value of 0.001 for complete viral clearance at day 7. All 38 subjects completed the seven-day treatment period, receiving either one of three ProLectin-M dose levels or matching placebo. Viral clearance was measured using RT-PCR analysis of nasopharyngeal swabs, with clearance defined as non-detection of viral RNA below http://www.streetinsider.com/FDA/Bioxytran+reports+complete+viral+clearance+in+phase+2+antiviral+trial/25978409.html Wed, 11 Feb 2026 06:00:27 +0000 A.50215973 BIXT O.07146130 O.07604345